Nemonoxacin not checked
TaiGen Biotechnology Co., Ltd. · TG-873870
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Community-acquired Pneumonia (2 trials), Diabetic Foot Infections, Pneumonia
- Main trialPhase 4
- “This study was to evaluate the safety and efficacy of oral nemonoxacin in treating elderly patients (aged ≥ 65 years) with community-acquired pneumonia (CAP).”In the company’s words, NCT05133752 on ClinicalTrials.gov
- Other names
- Taigexyn infusion solution · TG-873870 · Taigexyn
Other drugs for Community-acquired Pneumonia
- TrimodulinBiotest · Phase 3
- SR1375Shanghai SIMR Biotechnology Co., Ltd. · Phase 2
- OPT101Op-T LLC · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Completed | 23 Mar 2020 | Oral Nemonoxacin in Treating Elderly Patients With CAP | |
| Phase 3Completed | 4 May 2017 | A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP | |
| Phase 2Completed | Apr 2009 | Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections | |
| Phase 2Completed | Dec 2013 | Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026